Compare Freeport-McMoRan Inc (FCX) vs 10X Genomics Inc (TXG) Price & Performance

FCX trades at $73.29, up 1.98% on the day, with a bearish technical signal but strong fundamental support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is stable at $25.9B (2025), and net income margin improved to 11.38%. Analyst consensus is a Buy (60.97%), with a price target of $73.27. Recent news highlights copper demand growth driven by AI and data centers, positioning FCX to benefit.

FCX offers exposure to rising copper demand, supported by operational efficiency and expansion projects. Risks include cost pressures and regulatory scrutiny. The stock's valuation metrics (P/E 34.87, P/S 3.97) suggest premium pricing, requiring sustained earnings growth to justify upside. Institutional sentiment remains positive, but investors should monitor Q3 earnings and copper price trends.

TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.

The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.